UNSPSC 51434938: Hydrochlorothiazide/irbesartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434938 Hydrochlorothiazide/irbesartan is a Commodity code that captures state and local procurement of individual pharmaceutical products and active pharmaceutical ingredients for use in emergency medical services, hospital formularies, and public health programs. Recent state and local solicitations under this code show purchasing of specific branded and generic medications in measured quantities, with emphasis on supply chain compliance, manufacturing certifications, and expiration-date management. Issuing bodies include city fire and rescue departments (Tampa Fire Rescue via the City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances serving state departments and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The purchasing focus spans both individual emergency medications for field use and broader pharmaceutical product catalogs distributed through wholesaler networks to multiple member jurisdictions.

Recent activity concentrates in Texas, Florida, and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000 and a firm bid deadline of April 8, 2026; the solicitation includes a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for negotiated net-pricing models outside traditional PBM and GPO channels, signaling the state's intent to develop a formal RFP after this information-gathering phase. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with a response deadline of March 26, 2026 and contract effectiveness July 1, 2026; this multistate vehicle serves participating state and local government facilities across Minnesota and Oregon.